CR6086

Phase 2

AGENUS INC (AGEN)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

AGENPhase 2$385M

CR6086 Phase 2 Est. Readout

CR6086• Refractory Metastatic Colorectal Cancer107

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Refractory Metastatic Colorectal Cancer

View Full Landscape

Drug Information

Target Indication

Refractory Metastatic Colorectal Cancer

Clinical Trial

NCT05205330

Last updated: 10/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AGEN

AGENUS INC

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

HSPPC-96 or OncophagePhase 3

Malignant Melanoma

BalstilimabPhase 3

Advanced Melanoma

autologous human tumor-derived HSPPC-96Phase 3

Renal Cell Carcinoma

BotensilimabPhase 3

Metastatic Pancreatic Ductal Adenocarcinoma

FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)Phase 3

Resectable MMR-deficient Solid Tumors

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts